Fig. 5
From: Network integration of multi-tumour omics data suggests novel targeting strategies
Combined inhibition of PLK1 and proteasome in MCF-7 and T98G cells. MCF-7 (a) and T98G (b) cells were treated with increasing doses of Bortezomib (0.05–0.8 μM for MCF-7, 0.15–2.4 nM for T98G) and BI6727 (0.5–7.2 μM for MCF-7, 17–277 nM for T98G), alone or in combination, and cell viability was measured 72 h after drug administration by WST-1 assay (three independent experiments). Cell viability is represented as mean (error bars: s.d.). Statistical significance was determined by two-sided Student’s t test (*P < 0.05; ***P < 0.001). C.I. Combination Index (CompuSyn software). a MCF-7 cells: combinations with a C.I. lower than 0.5 are shown. b T98G cells: combinations showing synergistic effect are shown
